HomeCompareDCUE vs ABBV

DCUE vs ABBV: Dividend Comparison 2026

DCUE yields 19.37% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $79.1K in total portfolio value· pulled ahead in Year 2
10 years
DCUE
DCUE
● Live price
19.37%
Share price
$101.61
Annual div
$19.68
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.2K
Annual income
$2.23
Full DCUE calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — DCUE vs ABBV

📍 ABBV pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDCUEABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DCUE + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DCUE pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DCUE
Annual income on $10K today (after 15% tax)
$1,646.21/yr
After 10yr DRIP, annual income (after tax)
$1.90/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,054.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DCUE + ABBV for your $10,000?

DCUE: 50%ABBV: 50%
100% ABBV50/50100% DCUE
Portfolio after 10yr
$62.8K
Annual income
$12,387.00/yr
Blended yield
19.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

DCUE
Analyst Ratings
14
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$73.00
-28.2% upside vs current
Range: $69.00 — $77.00
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DCUE buys
0
ABBV buys
0
No recent congressional trades found for DCUE or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDCUEABBV
Forward yield19.37%3.06%
Annual dividend / share$19.68$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$23.2K$102.3K
Annual income after 10y$2.23$24,771.77
Total dividends collected$2.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$73.00$256.15

Year-by-year: DCUE vs ABBV ($10,000, DRIP)

YearDCUE PortfolioDCUE Income/yrABBV PortfolioABBV Income/yrGap
1$11,668$968.36$11,550$430.00+$118.00DCUE
2← crossover$13,013$528.00$13,472$627.96$459.00ABBV
3$14,199$275.16$15,906$926.08$1.7KABBV
4$15,333$140.30$19,071$1,382.55$3.7KABBV
5$16,478$70.80$23,302$2,095.81$6.8KABBV
6$17,667$35.55$29,150$3,237.93$11.5KABBV
7$18,921$17.81$37,536$5,121.41$18.6KABBV
8$20,254$8.91$50,079$8,338.38$29.8KABBV
9$21,677$4.46$69,753$14,065.80$48.1KABBV
10$23,196$2.23$102,337$24,771.77$79.1KABBV

DCUE vs ABBV: Complete Analysis 2026

DCUEStock

Dominion Energy, Inc. produces and distributes energy. The company operates through four segments: Dominion Energy Virginia, Gas Distribution, Dominion Energy South Carolina, and Contracted Assets. The Dominion Energy Virginia segment generates, transmits, and distributes regulated electricity to residential, commercial, industrial, and governmental customers in Virginia and North Carolina. The Gas Distribution segment engages in the regulated natural gas gathering, storage, transportation, distribution, and sales activities, as well as distributes nonregulated renewable natural gas. This segment serves residential, commercial, and industrial customers. The Dominion Energy South Carolina segment generates, transmits, and distributes electricity and natural gas to residential, commercial, and industrial customers in South Carolina. The Contracted Assets segment is involved in the energy marketing and price risk activities. As of December 31, 2021, the company's portfolio of assets included approximately 30.2 gigawatt of electric generating capacity; 10,700 miles of electric transmission lines; 78,000 miles of electric distribution lines; and 95,700 miles of gas distribution mains and related service facilities. It serves approximately 7 million customers. The company sells electricity at wholesale prices to rural electric cooperatives and municipalities, as well as into wholesale electricity markets. The company was formerly known as Dominion Resources, Inc. and changed its name to Dominion Energy, Inc. in May 2017. Dominion Energy, Inc. was incorporated in 1983 and is headquartered in Richmond, Virginia.

Full DCUE Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this DCUE vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DCUE vs SCHDDCUE vs JEPIDCUE vs ODCUE vs KODCUE vs MAINDCUE vs JNJDCUE vs MRKDCUE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.